Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
39
IGC Quote, Financials, Valuation and Earnings
Last price:
$0.28
Seasonality move
:
5.77%
Day range:
$0.28 - $0.29
52-week range:
$0.24 - $0.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20.81x
P/B ratio:
3.26x
Volume:
152.6K
Avg. volume:
401.4K
1-year change:
-1.7%
Market cap:
$26.4M
Revenue:
$1.3M
EPS (TTM):
-$0.08
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IGC
IGC Pharma, Inc.
|
$193K | -$0.02 | -40% | -35.14% | $4.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$292.6M | $0.14 | 15.84% | -39.95% | $31.80 |
|
AGEN
Agenus, Inc.
|
$28.1M | -$1.30 | 329.24% | -36.28% | $12.33 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.2B | $1.50 | 89.86% | -58.59% | $457.00 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$230.8M | -$0.37 | -87.74% | -73.49% | $81.36 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IGC
IGC Pharma, Inc.
|
$0.28 | $4.00 | $26.4M | -- | $0.00 | 0% | 20.81x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.56 | $31.80 | $4.2B | 10.73x | $0.00 | 0% | 3.89x |
|
AGEN
Agenus, Inc.
|
$3.33 | $12.33 | $120.4M | -- | $0.00 | 0% | 0.84x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$332.92 | $457.00 | $44.2B | 147.50x | $0.00 | 0% | 11.97x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$63.27 | $81.36 | $8.9B | 41.13x | $0.00 | 0% | 7.97x |
|
SVRA
Savara, Inc.
|
$6.02 | $10.81 | $1.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IGC
IGC Pharma, Inc.
|
1.82% | 0.511 | 0.39% | 0.78x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 3.124 | 1.15% | 3.40x |
|
AGEN
Agenus, Inc.
|
510.35% | 3.128 | 285.06% | 0.03x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 0.880 | 5.64% | 2.51x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
54.75% | 3.931 | 7.54% | 3.27x |
|
SVRA
Savara, Inc.
|
24.02% | -2.483 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IGC
IGC Pharma, Inc.
|
-$6K | -$2.9M | -91.27% | -94.42% | -1517.8% | -$2.4M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
AGEN
Agenus, Inc.
|
$26.6M | -$4.9M | -39.69% | -- | -16.08% | -$14.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$257.6M | $40.8M | 19.23% | 50.21% | 15.46% | $11.3M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
IGC Pharma, Inc. vs. Competitors
-
Which has Higher Returns IGC or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -953.4% compared to IGC Pharma, Inc.'s net margin of 96.33%. IGC Pharma, Inc.'s return on equity of -94.42% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About IGC or ACAD?
IGC Pharma, Inc. has a consensus price target of $4.00, signalling upside risk potential of 1342.48%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.80 which suggests that it could grow by 29.48%. Given that IGC Pharma, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe IGC Pharma, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IGCIGC Pharma, Inc.2 0 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is IGC or ACAD More Risky?
IGC Pharma, Inc. has a beta of 0.305, which suggesting that the stock is 69.522% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.661, suggesting its less volatile than the S&P 500 by 33.872%.
-
Which is a Better Dividend Stock IGC or ACAD?
IGC Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IGC or ACAD?
IGC Pharma, Inc. quarterly revenues are $191K, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. IGC Pharma, Inc.'s net income of -$1.8M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, IGC Pharma, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 10.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma, Inc. is 20.81x versus 3.89x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IGCIGC Pharma, Inc.20.81x -- $191K -$1.8M ACADACADIA Pharmaceuticals, Inc.3.89x 10.73x $284M $273.6M
-
Which has Higher Returns IGC or AGEN?
Agenus, Inc. has a net margin of -953.4% compared to IGC Pharma, Inc.'s net margin of -116.82%. IGC Pharma, Inc.'s return on equity of -94.42% beat Agenus, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M AGENAgenus, Inc.87.85% $1.94 $60.1M -
What do Analysts Say About IGC or AGEN?
IGC Pharma, Inc. has a consensus price target of $4.00, signalling upside risk potential of 1342.48%. On the other hand Agenus, Inc. has an analysts' consensus of $12.33 which suggests that it could grow by 270.37%. Given that IGC Pharma, Inc. has higher upside potential than Agenus, Inc., analysts believe IGC Pharma, Inc. is more attractive than Agenus, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IGCIGC Pharma, Inc.2 0 0 AGENAgenus, Inc.2 1 0 -
Is IGC or AGEN More Risky?
IGC Pharma, Inc. has a beta of 0.305, which suggesting that the stock is 69.522% less volatile than S&P 500. In comparison Agenus, Inc. has a beta of 1.567, suggesting its more volatile than the S&P 500 by 56.664%.
-
Which is a Better Dividend Stock IGC or AGEN?
IGC Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agenus, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma, Inc. pays -- of its earnings as a dividend. Agenus, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IGC or AGEN?
IGC Pharma, Inc. quarterly revenues are $191K, which are smaller than Agenus, Inc. quarterly revenues of $30.2M. IGC Pharma, Inc.'s net income of -$1.8M is lower than Agenus, Inc.'s net income of $63.9M. Notably, IGC Pharma, Inc.'s price-to-earnings ratio is -- while Agenus, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma, Inc. is 20.81x versus 0.84x for Agenus, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IGCIGC Pharma, Inc.20.81x -- $191K -$1.8M AGENAgenus, Inc.0.84x -- $30.2M $63.9M
-
Which has Higher Returns IGC or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -953.4% compared to IGC Pharma, Inc.'s net margin of 16.99%. IGC Pharma, Inc.'s return on equity of -94.42% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About IGC or ALNY?
IGC Pharma, Inc. has a consensus price target of $4.00, signalling upside risk potential of 1342.48%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.27%. Given that IGC Pharma, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe IGC Pharma, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IGCIGC Pharma, Inc.2 0 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is IGC or ALNY More Risky?
IGC Pharma, Inc. has a beta of 0.305, which suggesting that the stock is 69.522% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.361, suggesting its less volatile than the S&P 500 by 63.901%.
-
Which is a Better Dividend Stock IGC or ALNY?
IGC Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IGC or ALNY?
IGC Pharma, Inc. quarterly revenues are $191K, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. IGC Pharma, Inc.'s net income of -$1.8M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, IGC Pharma, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 147.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma, Inc. is 20.81x versus 11.97x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IGCIGC Pharma, Inc.20.81x -- $191K -$1.8M ALNYAlnylam Pharmaceuticals, Inc.11.97x 147.50x $1.1B $186.4M
-
Which has Higher Returns IGC or ARWR?
Arrowhead Pharmaceuticals, Inc. has a net margin of -953.4% compared to IGC Pharma, Inc.'s net margin of 10.7%. IGC Pharma, Inc.'s return on equity of -94.42% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 50.21%.
Company Gross Margin Earnings Per Share Invested Capital IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M ARWRArrowhead Pharmaceuticals, Inc.97.58% $0.22 $1.3B -
What do Analysts Say About IGC or ARWR?
IGC Pharma, Inc. has a consensus price target of $4.00, signalling upside risk potential of 1342.48%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $81.36 which suggests that it could grow by 28.6%. Given that IGC Pharma, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe IGC Pharma, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IGCIGC Pharma, Inc.2 0 0 ARWRArrowhead Pharmaceuticals, Inc.7 3 0 -
Is IGC or ARWR More Risky?
IGC Pharma, Inc. has a beta of 0.305, which suggesting that the stock is 69.522% less volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.227, suggesting its more volatile than the S&P 500 by 22.681%.
-
Which is a Better Dividend Stock IGC or ARWR?
IGC Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IGC or ARWR?
IGC Pharma, Inc. quarterly revenues are $191K, which are smaller than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $264M. IGC Pharma, Inc.'s net income of -$1.8M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $28.2M. Notably, IGC Pharma, Inc.'s price-to-earnings ratio is -- while Arrowhead Pharmaceuticals, Inc.'s PE ratio is 41.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma, Inc. is 20.81x versus 7.97x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IGCIGC Pharma, Inc.20.81x -- $191K -$1.8M ARWRArrowhead Pharmaceuticals, Inc.7.97x 41.13x $264M $28.2M
-
Which has Higher Returns IGC or SVRA?
Savara, Inc. has a net margin of -953.4% compared to IGC Pharma, Inc.'s net margin of --. IGC Pharma, Inc.'s return on equity of -94.42% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital IGCIGC Pharma, Inc.-3.14% -$0.02 $8.2M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About IGC or SVRA?
IGC Pharma, Inc. has a consensus price target of $4.00, signalling upside risk potential of 1342.48%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 79.61%. Given that IGC Pharma, Inc. has higher upside potential than Savara, Inc., analysts believe IGC Pharma, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IGCIGC Pharma, Inc.2 0 0 SVRASavara, Inc.6 0 0 -
Is IGC or SVRA More Risky?
IGC Pharma, Inc. has a beta of 0.305, which suggesting that the stock is 69.522% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.311, suggesting its less volatile than the S&P 500 by 68.931%.
-
Which is a Better Dividend Stock IGC or SVRA?
IGC Pharma, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. IGC Pharma, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IGC or SVRA?
IGC Pharma, Inc. quarterly revenues are $191K, which are larger than Savara, Inc. quarterly revenues of --. IGC Pharma, Inc.'s net income of -$1.8M is higher than Savara, Inc.'s net income of -$29.6M. Notably, IGC Pharma, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for IGC Pharma, Inc. is 20.81x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IGCIGC Pharma, Inc.20.81x -- $191K -$1.8M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Mar 2
Applied Optoelectronics, Inc. [AAOI] is up 21.71% over the past day.
Buy
90
BNAI alert for Mar 2
Brand Engagement Network, Inc. [BNAI] is up 2.44% over the past day.
Sell
36
WLDN alert for Mar 2
Willdan Group, Inc. [WLDN] is down 1.93% over the past day.
